HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SAKAI, F. Articles by SAEZ, S. Search for Related Content PubMed Articles by SAKAI, F. Articles by SAEZ, S.

The effects of tamoxifen on cortisol binding globulin (CBG) and sex hormone binding globulin (SHBG) were studied in 25 women and one man with breast cancer. These patients were in various endocrine states according to age (15 post-menopausal women) or previous endocrine surgery (ovariectomy, two patients; ovariectomy plus adrenal surgery, five patients; hypophysectomy, three patients; ovariectomy plus hypophysectomy, two patients). The administration of tamoxifen (20–40 mg/day) resulted in increases in the level of CBG in all patients (mean rise in binding capacity 10·8 µg cortisol/100 ml plasma) and in the level of SHBG in 21 patients (mean rise in binding capacity 0·79 µg dihydrotestosterone/ 100 ml plasma for all patients). These increases were positively correlated. They were not associated with any alteration in the association constants of the steroid binding globulins. The effect of tamoxifen on CBG diminished with increasing age. The changes in the levels of CBG and SHBG were independent of the endocrinological state of the patient. It is inferred that tamoxifen has a direct oestrogen-like action on the liver which results in increased production of CBG and SHBG. Tamoxifen therapy for carcinoma of the breast appeared to be least effective in those patients in whom the drug caused the highest increase in the concentration of CBG.

This article has been cited by other articles:

				M. Dowsett, C. Pfister, S. R. D. Johnston, D. W. Miles, S. J. Houston, J. A. Verbeek, H. Gundacker, A. Sioufi, and I. E. Smith Impact of Tamoxifen on the Pharmacokinetics and Endocrine Effects of the Aromatase Inhibitor Letrozole in Postmenopausal Women with Breast Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2338 - 2343. [Abstract] [Full Text] [PDF]

				J. N. Ingle, V. J. Suman, P. A. Johnson, J. E. Krook, J. A. Mailliard, R. H. Wheeler, C. L. Loprinzi, E. A. Perez, V. C. Jordan, and M. Dowsett Evaluation of Tamoxifen plus Letrozole with Assessment of Pharmacokinetic Interaction in Postmenopausal Women with Metastatic Breast Cancer Clin. Cancer Res., July 1, 1999; 5(7): 1642 - 1649. [Abstract] [Full Text] [PDF]